At the Revolutionary Atopic Dermatitis (RAD) Conference held in Nashville, Tennessee in 2025, the pathophysiology of chronic pruritus and treatment progress became a highly focused topic of discussion. Dr. Gil Yosipovitch, a professor of dermatology at the Miller School of Medicine in Miami, the chair of Stifel Medical Dermatology, and the director of the Miami Pruritus Center, shared his profound insights into the treatment of chronic pruritus at the conference, bringing new inspirations to research and clinical practice in this field.
“I like RAD because I think it emphasizes many components of skin inflammation, and atopic dermatitis is a good marker disease. The inflammatory immune system works together with the nervous system, so we can learn a lot from RAD to treat other diseases involving skin inflammation,” Yosipovitch said in an interview with Dermatology Times. At this conference, he discussed the multi-factor mechanisms and treatment strategies of chronic pruritus inside and outside atopic dermatitis (AD) under the title “Pearls for Treating Pruritus”, and his content went beyond AD and extended to other skin diseases characterized by chronic pruritus.
At the conference, Yosipovitch first explored the development trends of biological agents and small molecule drugs that regulate type 2 inflammation and neuroimmune signaling. He pointed out that IL-4, IL-13, and IL-31 blocking therapies have shown significant antipyretic effects in the treatment of AD and pruritus syndrome. Among them, drugs such as dupilumab, lebrikizumab, and nemolizumab can not only effectively inhibit inflammatory responses but also directly reduce the intensity of pruritus. Additionally, JAK inhibitors such as abrocitinib and povorcitinib, due to their downstream effects on various itch-related cytokine pathways, have also attracted much attention in the treatment of chronic pruritus. The emergence of these drugs provides powerful weapons to solve the problem of chronic pruritus from its inflammatory root.
Related Topics:
